Early research (Phase 1)Study completedNCT03010982
What this trial is testing
Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors
Who this might be right for
Diffuse Large B Cell LymphomaPrimary Mediastinal LymphomaMantle-Cell Lymphoma+3 more
Epizyme, Inc. 3